A Multicentre, Open-label, Three-arm Randomised Phase II Trial Assessing the Safety and Efficacy of the HSP90 Inhibitor Ganetespib in Combination With Carboplatin Followed by Maintenance Treatment With Niraparib Versus Ganetespib Plus Carboplatin Followed by Ganetespib and Niraparib Versus Carboplatin in Combination With Standard Chemotherapy Followed by Niraparib Maintenance Treatment in Platinum-sensitive Ovarian Cancer Patients

This study will be performed in women with platinum-sensitive, high-grade serous, high-grade endometrioid, undifferentiated epithelial ovarian cancer, carcinosarcoma, fallopian tube or primary peritoneal cancer (proven by central histo-pathological review).
A total of 120 subjects will be randomized (1:1:1) to three different treatment arms: (A) Standard arm (arm A): Carboplatin (AUC5 d1, q3w i.v.) in combination with Paclitaxel (175 mg/m² d1, q3w i.v.) or Carboplatin (AUC4 d1, q3w i.v.) in combination with Gemcitabine (1000 mg/m² d1, d8, q3w i.v.) followed by maintenance therapy with Niraparib (200/ 300 mg oral daily, q4w) // (B) First experimental arm (arm B): Ganetespib (150 mg/m2, d1, q3w) in combination with Carboplatin (AUC5 d1, q3w i.v.) followed by maintenance treatment with Niraparib (200/ 300 mg oral daily, q4w) // (C) Second experimental arm (arm C): Ganetespib (150 mg/m² d1, q3w i.v.) plus Carboplatin (AUC5 d1, q3w i.v.) followed by Ganetespib (100 mg/m² d1, d8, d15, d22, q4w i.v.) and Niraparib (200 mg oral daily, q4w).
Chemotherapy treatment will be given for 6 cycles, maintenance treatment with Ganetespib will be given for a maximum of 9 months or until disease progression, maintenance treatment with Niraparib can continue until disease progression.

Start Date30 Nov 2018

Sponsor / Collaborator

Universitaire Ziekenhuizen Leuven

NCT02637375

/ WithdrawnNot ApplicableIIT

A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer

Based on preclinical data implicating GR, AR, and JAK/STAT activation as potent mechanisms of breast cancer cell survival despite chemotherapy administration (i.e. chemotherapy resistance), the study will test a novel approach for improving chemotherapy effectiveness by adding Hsp90 inhibition to antagonize the anti-apoptotic signaling pathways that are initiated via GR, AR, and JAK/STAT activation.

Start Date01 May 2016

Sponsor / Collaborator

The University of Chicago

NCT02389751

/ CompletedPhase 1IIT

GUARDIAN-1 Trial: A Phase 1 Study of Ganetespib in Combination With Chemoradiation for Stage II-III Esophageal Carcinoma

This phase I trial studies the side effects and best dose of ganetespib when given together with paclitaxel, carboplatin, and radiation therapy in treating patients with stage II-III esophageal cancer. Ganetespib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving ganetespib in combination with paclitaxel, carboplatin, and radiation therapy may be a better treatment for patients with esophageal cancer.

Start Date10 Apr 2015

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+1]

100 Clinical Results associated with Ganetespib

100 Translational Medicine associated with Ganetespib

100 Patents (Medical) associated with Ganetespib

330

Literatures (Medical) associated with Ganetespib

01 Jan 2025·Critical reviews in oncogenesis

Molecular Dynamics of Adenomatous Polyposis Coli (APC) Protein and Its Inhibitors: A Special Insight to Colorectal Cancer

Review

Author: Kumari, Rina ; Rathod, Rajeshwari ; Ghava, Dilip ; Kumar, Sunil ; Behera, Santosh Kumar ; Panda, Amrita Kumari

Colorectal cancer (CRC) initiates in colon or rectum is named as colon or rectal cancer, based on the site of inception. Various genetic alterations responsible for CRC include several signaling pathways. The Wingless/Wnt signaling pathway is the vital pathway which involved in the cancer pathogenesis. The hallmark of human CRC is adenomatous polyposis coli (APC), a negative regulator of the Wnt pathway. Mutations in the APC gene is a critical event in the development of human CRC which may lead to overexpression and stabilization of β-catenin that enters into the nucleus and helps in cancer cell proliferation. Significant obstacles to the therapeutic intervention of the Wnt signaling system still exist, despite promising approaches for the development of anti-cancer medicines targeting this route. The advent of computational techniques for cancer diagnosis, prognosis, and drug development has spurred the researchers to explore CRC at an early stage. This report had unzipped the importance of APC in Wnt signaling pathway associated with current advances and challenges in drug discovery for CRC. A combinatorial computational approach identified the potential anti-cancerous drug among XL888, 5-bromouracil, 5-fluorouracil, and Ganetespib against APC which is often treated as gatekeeper of CRC. This in silico investigation revealed Ganetespib as a potential anti-cancerous drug against APC for CRC therapeutics, which will be an alternative to chemotherapy. In vitro and in vivo studies are needed further to confirm the efficiency and evaluate potency of Ganetespib against the target.

01 Jan 2025·JOURNAL OF LIPID RESEARCH

Hsp90α promotes lipogenesis by stabilizing FASN and promoting FASN transcription via LXRα in hepatocellular carcinoma

Article

Author: Wu, Yingxia ; Cen, Shengpei ; Li, Jieyou ; Su, Hairou ; Liang, Manfeng ; Huang, Yaling ; Zhou, Zhifeng ; Zou, Fei ; Liu, Yilin ; Zheng, Zhenming ; Chen, Yukui ; Deng, Zihao ; Chen, Xuemei ; Wu, Guibing ; Liao, Yandan ; Zhang, Jinxin ; Deng, Yaotang ; Shi, Xiongjie ; Li, Yan ; Liu, Lixia ; Tan, Wenchong ; Xie, Guantai

Excessive lipid accumulation promotes the occurrence and progression of hepatocellular carcinoma (HCC), accompanied by high levels of fatty acid synthetase (FASN) and more active lipogenesis. Heat shock protein 90 (Hsp90) acts as a chaperone to maintain the stability and activity of the client proteins. Studies have revealed that Hsp90 regulates the lipid metabolism of HCC, but the effect of Hsp90 on FASN still remains unknown. This study aims to discover the mechanism of Hsp90 inhibition on lipid accumulation and investigate the different effects of Hsp90 N-terminal domain inhibitor STA9090 and C-terminal domain inhibitor novobiocin on FASN protein stability and transcription pathway in HCC. We found that HCC cells tended to store lipids, which could be disrupted by Hsp90 inhibitors in vivo and in vitro. High levels of Hsp90α and FASN in tumor tissue had correlation with poor prognosis of HCC patients, and Hsp90α interacted with FASN to maintain its protein stability. Furthermore, N-terminal domain of Hsp90α was essential for process of sterol regulatory element binding protein 1 to activate FASN transcription and Hsp90α prevented proteasomal degradation of liver X receptor α to upregulate FASN transcription via liver X receptor α/sterol regulatory element binding protein 1 axis. Our data reveal that Hsp90α promotes lipid accumulation by increasing the protein stability and FASN mRNA transcription, and can be alleviated by Hsp90 inhibitors, which provides a theoretical basis for Hsp90-targeted therapy on lipid metabolism in HCC.

01 Jan 2025·Critical reviews in oncogenesis

Interaction of Heat Shock Protein 90 (HSP90), Ganetespib, and 5-Fluorouracil by Computational Approach for Colorectal Cancer Therapy

Article

Author: Alam, Afroz ; Golivi, Yuvasri ; Behera, Santosh Kumar ; Peela, Sujatha

The heat shock protein 90 kDa (HSP90) is highly conserved across diverse species, including humans, and upregulated in various cancers. As a result, it has been identified as a promising target for advancing anticancer medicine. The introduction of combinatorial chemistry in drug discovery has emphasized the need to develop new technologies in screening, designing, decoding, synthesizing, and screening combinatorial drug libraries. The current investigation was carried out to report improved inhibition efficacy of ganetespib, fluorouracil (5-FU), and its combinatorial drug treatment (ganetespib + 5-FU) against the HSP90 molecular chaperone through an in silico approach. Both drugs and their combination are ATP-competitive inhibitors; they inhibit the HSP90α N-terminal and block the ATP binding site. The structural and functional basis and their combination were confirmed through molecular docking interaction with HSP90α. The inhibitors' conformational effects and their combination against the HSP90α protein were studied using powerful MD simulations. The key interacting residues of HSP90α with ganetespib, 5-FU, and ganetespib + 5-FU were identified via energy binding calculations and molecular dynamics. This study is the first to offer atomistic insights into the interaction between ganetespib, 5-FU, and ganetespib + 5-FU with the HSP90α protein N-terminal domain. The results of our in silico study will open better avenues for developing potential cancer inhibitors in the near future.

News (Medical) associated with Ganetespib

16 May 2024

·www.biospace.com

Angle PLC Announces Study of Ovarian Cancer CTCs Using Parsortix

INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALS The study investigated 123 metastatic ovarian cancer patients over two and a half years using the Parsortix system to assess 474 longitudinal patient samples Downstream qPCR molecular analysis of the Parsortix harvest for ESR1 and ERCC1 genes may be an early predictor of progression free survival and cancer progression respectively GUILDFORD, SURREY / ACCESSWIRE / May 16, 2024 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is delighted to announce the publication of a study using the Parsortix® system to identify markers present in CTCs harvested from metastatic mutant-p53 platinum-resistant ovarian cancer (PROC) patients. The study was conducted as an offshoot of the European multi-centre GANNET53 Phase II clinical trial (NCT02012192) funded by the EU 7th Framework Programme (Grant agreement ID: 602602). The study investigated the efficacy of ganetespib in combination with paclitaxel vs. paclitaxel alone. Patients were enrolled across 12 clinical centres in Germany, Belgium, France, and Austria. The translational study, which the research team believes is the largest study of CTCs in ovarian cancer (in terms of number of patient samples analysed), was conducted by researchers at the Medical University of Vienna, Austria. The study analysed a total of 474 blood samples collected from 123 PROC patients at baseline (i.e. prior to first administration of study drugs), and at multiple timepoints over a period of two and a half years during treatment until disease progression. A panel of 27 gene transcripts (RNA) was analysed on Parsortix-harvested CTCs using standard laboratory qPCR analysis. The authors identified two CTC-associated markers with potential prognostic value. ERCC1, a key gene of the DNA damage response pathway, was associated with an increased risk of disease progression and worse outcomes, whereas the presence of ESR1, a gene encoding oestrogen receptor alpha (ERα), was associated with a reduced progression risk. The presence of ESR1 transcripts together with concurrent absence of ERCC1 transcripts in CTC-enriched samples at baseline and during treatment cycles was found to be predictive of improved progression free survival (PFS). Whereas the presence of ERCCI transcripts and the absence of ESR1 transcripts at baseline and during treatment cycles indicated a 12.77× greater likelihood (odds ratio) of cancer progression. The analysis of these biomarkers has the potential to provide an early indication of PFS ahead of clinical trial results and suggests that CTC characterisation may be a valuable tool for pharma drug trials in the future. In addition, the authors conclude that molecular characterisation of CTCs before and during treatment has the potential to be a useful tool to monitor ovarian cancer patients and may provide further insights into the biology of this difficult to treat disease. According to clinicaltrials.gov there are 1,024 active interventional studies enrolling more than 825,000 participants in ovarian cancer. The study is published as a peer-reviewed journal article in the International Journal of Cancer and is available online at ANGLE Chief Scientific Officer, Karen Miller, commented: "We are pleased to share this peer-reviewed publication by the Medical University of Vienna and the European GANNET53 consortium. The paper demonstrates the potential utility of molecular characterisation of CTCs enriched using the Parsortix system in monitoring ovarian cancer patients throughout their treatment and during follow-up. The scale of this study, both in terms of numbers of patients and timescale of follow-up, is particularly important. It clearly demonstrates how use of the Parsortix system in cancer trials could in the future enable our pharma customers to gain an early understanding of how patients are responding to their drug." Ovarian cancer accounted for over 320,000 new cases of cancer, and over 200,000 deaths worldwide in 20221. Diagnosis often occurs at a later stage, and although patients often respond well to initial treatment with a platinum-based chemotherapy, many patients relapse and develop resistance to treatment2. 1. American Cancer Society. Global Cancer Facts & Figures 5th Edition. Atlanta: American Cancer Society; 2024 2. Zamwar UM, Anjankar AP. Aetiology, epidemiology, histopathology, classification, detailed evaluation, and treatment of ovarian cancer. Cureus. 2022; 14:e30561 ANGLE plc +44 (0) 1483 343434 Andrew Newland, Chief Executive Ian Griffiths, Finance Director Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800 FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) +44 (0) 203 727 1000 +1 (212) 850 5624 For Research Use Only. Not for use in diagnostic procedures. For Frequently Used Terms, please see the Company's website on Notes for editors About ANGLE plc ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system, associated consumables and assays. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Over 90 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit . SOURCE: ANGLE plc View the original press release on accesswire.com

Phase 2Clinical Result

21 Sep 2023

·synapse.patsnap.com

Analysis on the Research Progress of HSP90 inhibitors

Heat shock protein 90 (HSP90) is an ATP-dependent molecular chaperone essential in eukaryotic organisms. It is ubiquitously present in both prokaryotic and eukaryotic cells, excluding archaea, and is one of the core members of the heat shock protein family. In normal cells, HSP90 makes up 1-2% of the total proteins, this percentage increasing to 4-6% under stressful conditions. Moreover, HSP90 is highly conserved evolutionarily, with its function being consistent across cells of different species origins. Molecular chaperone proteins in cells play a critical role in protein folding through their binding with substrate proteins. HSP90 is such a molecular chaperone protein, capable of high activation in the harsh tumour environment of various solid tumours, yet remains relatively dormant in normal tissues. Therefore, it is considered a potential target for tumour drug development. In addition, HSP90 serves as a downstream modulator for the signaling of Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-17A (IL-17A). HSP90 Competitive LandscapeAccording to the data provided by Patsnap Synapse-Global Drug Intelligence Database: the following figure shows that as of 18 Sep 2023, there are a total of 55 HSP90 drugs worldwide, from 67 organizations, covering 78 indications, and conducting 224 clinical trials. 👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs , indications, organizations, clinical trials, clinical results, and drug patents related to this target. The analysis of the target HSP90 reveals a competitive landscape with companies like Wakamoto Pharmaceutical Co., Ltd., D. Western Therapeutics Institute, Inc., and Samus Therapeutics LLC leading the way in R&D efforts. The indications with approved drugs include Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Glaucoma. Small molecule drugs, including small molecule-drug conjugates, are progressing rapidly, indicating the primary focus of R&D efforts. The European Union, the United Kingdom, and Japan are the fastest-developing regions, with emerging markets in China and South Korea. Overall, the target HSP90 shows promising potential for the development of innovative drugs in various indications, with a strong focus on small molecule drugs. HSP90 inhibitors entering Phase III clinical trials: GanetespibGanetespib is a small molecule drug that falls under the category of biomedicine. It specifically targets HSP90, a protein that plays a crucial role in the folding and stabilization of other proteins. By inhibiting HSP90, Ganetespib aims to disrupt the function of various proteins involved in disease processes. The therapeutic areas in which Ganetespib is being explored include neoplasms (abnormal growth of cells), endocrinology and metabolic diseases, urogenital diseases, and hemic and lymphatic diseases. These broad therapeutic areas suggest that Ganetespib has the potential to be effective in treating a wide range of conditions. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. Currently, Ganetespib is being investigated for its efficacy in treating several specific indications. These include myelodysplastic syndromes (a group of disorders characterized by abnormal blood cell production), acute myeloid leukemia (a type of cancer that affects the blood and bone marrow), mesothelioma (a rare cancer that affects the lining of the lungs, abdomen, or heart), and ovarian cancer. The drug is developed by Synta, Inc., an originator organization in the pharmaceutical industry. Synta, Inc. is responsible for the discovery and development of Ganetespib, and they hold the rights to the drug. In terms of its development stage, Ganetespib has reached Phase 3 of clinical trials. This indicates that the drug has already undergone extensive testing in preclinical and early clinical stages and has shown promising results. Phase 3 trials involve a larger number of participants and aim to further evaluate the drug's safety and effectiveness compared to existing treatments or a placebo. In summary, Ganetespib is a small molecule drug that targets HSP90 and is being investigated for its potential in treating various neoplasms, endocrinology and metabolic diseases, urogenital diseases, and hemic and lymphatic diseases. It is currently in Phase 3 clinical trials and is being developed by Synta, Inc. LuminespibLuminespib is a small molecule drug that falls under the category of biomedicine. It specifically targets HSP90, a protein involved in various cellular processes. The drug is primarily developed for the treatment of neoplasms, which are abnormal growths of tissue commonly referred to as tumors. Luminespib has shown potential in treating specific types of neoplasms, including head and neck neoplasms, adenocarcinoma of the lung, and squamous cell carcinoma. These indications suggest that the drug may be effective in combating various forms of cancer. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. The drug's originator organization is Ligand UK Ltd., a pharmaceutical company involved in the research and development of innovative therapies. This suggests that Luminespib is a product of extensive scientific research and development efforts. In terms of its development stage, Luminespib has reached Phase 2, which is considered a significant milestone in the drug development process. Phase 2 trials involve testing the drug on a larger group of patients to evaluate its safety and efficacy. The fact that Luminespib has reached this stage indicates that it has shown promising results in earlier stages of development. It is worth noting that Luminespib has reached Phase 2 in both global and Chinese markets. This suggests that the drug has gained recognition and interest not only internationally but also within the Chinese pharmaceutical industry. In terms of regulation, Luminespib is classified under the Special Review Project. This classification implies that the drug may have unique characteristics or potential benefits that warrant special attention from regulatory authorities. In summary, Luminespib is a small molecule drug developed by Ligand UK Ltd. It targets HSP90 and shows potential in treating various neoplasms, including head and neck neoplasms, adenocarcinoma of the lung, and squamous cell carcinoma. The drug has reached Phase 2 in both global and Chinese markets, indicating promising results in earlier stages of development. Luminespib falls under the Special Review Project category, suggesting unique characteristics or potential benefits that require special regulatory attention.

10 Mar 2021

·www.biospace.com

Aldeyra Therapeutics to Present at the OIS Dry Eye Innovation Showcase on March 11, 2021

March 10, 2021 13:00 UTC LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D. will discuss the potential of reproxalap as a novel, rapid-onset first-line treatment for dry eye disease as part of the Ophthalmology Innovation Summit’s Dry Eye Disease Innovation Showcase, which will take place virtually on Thursday, March 11, 2021 from 1:00 p.m. to 4:00 p.m. ET. The event will include a market overview and company presentations as well as panel discussions featuring experts who will provide industry and clinical perspectives on the dry eye disease market. Registration is complimentary. To register, click here: About Aldeyra Therapeutics, Inc. Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer. For more information, visit and follow us on LinkedIn, Facebook, and Twitter.

100 Deals associated with Ganetespib

External Link

KEGG	Wiki	ATC	Drug Bank
D10126	-	-	DB12047

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Myelodysplastic Syndromes	Phase 3	United Kingdom	-	07 Jul 2014
Acute Myeloid Leukemia	Phase 3	Denmark	-	01 Jul 2014
Advanced Lung Non-Small Cell Carcinoma	Phase 3	United States	Synta Pharmaceuticals Corp.	01 Apr 2013
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Austria	Synta Pharmaceuticals Corp.	01 Apr 2013
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Belgium	Synta Pharmaceuticals Corp.	01 Apr 2013
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Bosnia and Herzegovina	Synta Pharmaceuticals Corp.	01 Apr 2013
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Canada	Synta Pharmaceuticals Corp.	01 Apr 2013
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Croatia	Synta Pharmaceuticals Corp.	01 Apr 2013
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Czechia	Synta Pharmaceuticals Corp.	01 Apr 2013
Advanced Lung Non-Small Cell Carcinoma	Phase 3	France	Synta Pharmaceuticals Corp.	01 Apr 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01042379 (I-SPY2, Pubmed)	Phase 2	Breast Cancer Neoadjuvant	233	Ganetespib	fykzaetcdx(dbmubukhbe) = lwqpsttkck vdpqzoisjf (hfktuqcvtg )	-	01 Dec 2022
				Standard NAC control	fykzaetcdx(dbmubukhbe) = nppijnxygc vdpqzoisjf (hfktuqcvtg )
NCT01042379 (I-SPY2, ASCO2022) Manual	Phase 2	Triple Negative Breast Cancer Neoadjuvant HER2 Negative \| ER Negative \| PR Negative	363	pembrolizumab (Immune+ TNBC)	sntcmvlffi(pikfeqbfry) = xzosqtwneh lvlyqbhgla (iwtaaapttt )	Positive	02 Jun 2022
				carboplatin (VC) (Immune+ TNBC)	sntcmvlffi(pikfeqbfry) = mihtebsvus lvlyqbhgla (iwtaaapttt )
NCT01167114 (Pubmed \| Invest New Drugs) Manual	Phase 2	Neoplasms Second line	26	Ganetespib	axqizwwxbu(orttslwpyq) = zucwbkuxpk uvnrnjrmod (qsyvljwsra ) View more	Negative	01 Oct 2020
NCT01590160 (MESO-02, Pubmed \| Clin Cancer Res) Manual	Phase 1	Malignant Pleural Mesothelioma	27	pemetrexed+cisplatin+carboplatin+Ganetespib	wnfaeixnzc(iqwqvtkgsc) = dlbrkqyvfx sopwhiloer (nzssduuydv ) View more	Positive	15 Sep 2020
NCT02008877 (SARC023, Pubmed) Manual	Phase 1/2	Sarcoma \| Neurofibrosarcoma	20	Sirolimus+Ganetespib (phase 1 ：refractory sarcoma)	igxeyqmrqa(xyebegrsib) = jhkquwhjaa wjmfrueeev (jbgslpdkag )	Negative	30 Jan 2020
				Sirolimus+Ganetespib (phase 2 ： MPNST)	igxeyqmrqa(xyebegrsib) = kkqhgknphy wjmfrueeev (jbgslpdkag )
NCT02012192 (GANNET53, Pubmed) Manual	Phase 1/2	Ovarian Epithelial Carcinoma	10	Paclitaxel+Ganetespib (cohort 1)	wbyjuqlocu(ndfhlpvzez) = nieivioyyj ntsrygayca (egygttnifg )	Positive	10 Sep 2019
				Paclitaxel+Ganetespib (cohorts 2 and 3)	wbyjuqlocu(ndfhlpvzez) = vkelpdbxrk ntsrygayca (egygttnifg )
NCT02012192 (GANNET53, CTgov)	Phase 1/2	Primary Peritoneal High-Grade Serous Adenocarcinoma \| Platinum-Resistant Primary Peritoneal Carcinoma \| Ovarian Epithelial Carcinoma ... View more	133	Ganetespib+Paclitaxel (Ganetespib + Paclitaxel)	tcpynajfoc(hrfmpvxcrm) = fejizwfzjs cpnouvxvaw (wdfwvkbhqk, cgiyhhrvqq - yddwhwcwfi) View more	-	13 Aug 2019
				Paclitaxel (Paclitaxel)	tcpynajfoc(hrfmpvxcrm) = iojmxtkhjt cpnouvxvaw (wdfwvkbhqk, ivntahoqvk - gptpowkzyq) View more
NCT02008877 (SARC023, CTgov)	Phase 1/2	Neurofibrosarcoma	20	ganetespib+Sirolimus	eqrevxnihj = egelgjifuw ggxprupntj (qhurfmvrbn, zecbwudfim - rminmsjywr) View more	-	02 May 2019
NCT01560416 (CTgov)	Phase 2	Hormone receptor positive breast cancer	50	Fulvestrant (ARM A - Fulvestrant)	xgwqmksang(qzyalzhlum) = coysrlralb rotnwtjirx (kjuhdfsdfi, yqvokrenpt - frhbldpblr) View more	-	03 Jan 2019
				Ganetespib+Fulvestrant (Arm B - Fulvestrant+Ganetespib)	xgwqmksang(qzyalzhlum) = ayvhaojamr rotnwtjirx (kjuhdfsdfi, cshvffgysf - bliscpldqt) View more
NCT01200238 (Pubmed) Manual	Phase 2	Uveal Melanoma	17	ganetespib (cohort A)	onbjumrtpm(bpanigpfre) = kjuerniybr thiicblerk (vubuedacov ) View more	Negative	01 Dec 2018
				ganetespib (cohort B)	onbjumrtpm(bpanigpfre) = ejmjdjnswj thiicblerk (vubuedacov ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis